Acyclic ribooxacarbenium ion mimics as transition state analogues of human and malarial purine nucleoside phosphorylases

Journal of the American Chemical Society

Volumn 129, Issue 22, 2007, Pages 6984-6985

  Taylor, Erika A ^a   Clinch, Keith ^b   Kelly, Peter M ^b   Li, Lei ^a   Evans, Gary B ^b   Tyler, Peter C ^b   Schramm, Vern L ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b CALLAGHAN INNOVATION   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

9 DEAZAHYPOXANTHINE; AMINOALCOHOL; ANTIMALARIAL AGENT; CARBON; DEOXYGUANOSINE; GUANOSINE; HYDROXYL GROUP; HYPOXANTHINE; IMMUCILLIN G; IMMUCILLIN H; IMMUNOSUPPRESSIVE AGENT; INOSINE; PURINE NUCLEOSIDE DERIVATIVE; PURINE NUCLEOSIDE PHOSPHORYLASE; PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR; RIBOOXACARBENIUM ION; TRANSITION ELEMENT; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE;

ARTICLE; BINDING AFFINITY; CANCER RELAPSE; CANCER RESISTANCE; CATALYSIS; CELLULAR IMMUNITY; CLINICAL TRIAL; DISSOCIATION CONSTANT; DRUG BINDING; DRUG SCREENING; DRUG TARGETING; ENZYME STRUCTURE; GENETIC DISORDER; HUMAN; IMMUNE DEFICIENCY; MALARIA; NONHUMAN; PHENOTYPE; PLASMODIUM FALCIPARUM; PROTEIN EXPRESSION; PROTEIN FOLDING; SYNTHESIS; T CELL LEUKEMIA;

ANIMALS; BIOMIMETIC MATERIALS; HUMANS; IMINES; KINETICS; PLASMODIUM FALCIPARUM; PURINE-NUCLEOSIDE PHOSPHORYLASE; PYRIMIDINONES; PYRROLIDINES;

EID: 34250205219     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja071087s     Document Type: Article

References (15)

1. Stoeckler, J. D. Developments in Cancer Chemotherapy; Glazer, R. J., Ed.; CRC Press: Boca Raton, FL, 1984; pp 35-60.
2. Bantia, S.; Kilpatrick, J. M. Curr. Opin. Drug Discovery Dev. 2004, 7, 243-247.
3. Kicska, G. A.; Tyler, P. C.; Evans, G. B.; Furneaux, R. H.; Schramm, V. L.; Kim, K. J. Biol. Chem. 2002, 277, 3226-3231.
4. Schramm, V. L. Nucleosides Nucleotides Nucleic Acids 2004, 23, 1305-1311.
5. Giblett, E. R.; Ammann, A. J.; Wara, D. W.; Sandman, R.; Diamond, L. K. Lancet 1975, 1, 1010-1013.
6. Kline, P. C.; Schramm, V. L. Biochemistry 1993, 32, 13212-13219.
7. Miles, R. W.; Tyler, P. C.; Furneaux, R. H.; Bagdassarian, C. K.; Schramm, V. L. Biochemistry 1998, 37, 8615-8621.
8. Evans, G. B; Furneaux, R. H.; Hutchison, T. L.; Kezar, H. S.; Morris, P. E., Jr.; Schramm, V. L.; Tyler, P. C. J. Org. Chem. 2001, 66, 5723-5730.
9. See http://www.biocryst.com/index.htm.
10. Lewandowicz, A.; Schramm, V. L. Biochemistry 2004, 43, 1458-1468.
11. Lewandowicz, A.; Tyler, P. C.; Evans, G. B.; Furneaux, R. H.; Schramm, V. L. J. Biol. Chem. 2003, 278, 31465-31468.
12. Lewandowicz, A.; Taylor Ringia, E. A.; Ting, L.-M.; Kim, K.; Tyler, P. C.; Evans, G. B.; Zubkova, O. V.; Mee, S.; Painter, G. P.; Lenz, D. H.; Furneaux, R. H.; Schramm, V. L. J. Biol. Chem. 2005, 280, 30320-30328.
13. Semeraro, T.; Lossani, A.; Botta, M.; Ghiron, C.; Alvarez, R.; Manetti, F.; Mugnaini, C.; Valensin, S.; Focher, F.; Corelli, F. J. Med. Chem. 2006, 49, 6037-6045.
14. Compound 8 is a mixture of enantiomers, and therefore the inhibition value likely reflects an average inhibition value, where one enantiomer is likely to have a smaller dissociation constant.
15. i* in cases where slow-onset inhibition occurs (see Supporting Information).